

**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Timothy A. Bird, Jacques J. Peschon, John E. Sims,  
G. Duke Virca and Cynthia R. Willis

Serial No.: 09/884,001

Group Art Unit No.: 1642

Filed: June 18, 2001

Examiner: Susan Ungar

For: sGNK POLYPEPTIDES (as amended)

Docket No.: 2009-US

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, applicants submit a copy of the "List of References Cited by Applicant" as filed January 15, 2003 on a modified PTO-1449 form for consideration by the Examiner.

In response to Office Action mailed on July 15, 2003, submission of the references cited are being enclosed as requested by the Examiner for her convenience. As noted on the Information Disclosure Statement filed January 15, 2003, the present application is a continuation of application Serial No. PCT/US99/29989 filed June 18, 2001, which is relied upon for an earlier filing date under 35 USC 120.

In accordance with 37 CFR 1.98(d), copies of the patents, publications or other information listed in this information disclosure statement (B1 - B3 and C1 - C4) are not required to be provided and are not enclosed because they were previously cited in prior application Serial No. PCT/US99/29989, International Publication No. WO/00/36097. The present application is a continuation of application Serial No. PCT/US99/29989 filed June 18, 2001, which is relied upon for an earlier filing date under 35 USC 120.

Applicants request consideration of this information and passage of the application to issue.

**EXPRESS MAIL CERTIFICATE**

"Express Mail" mail labeling number: EV 352488508 US

Date of Deposit: January 15, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sherry St. Andrew


Printed Name



Signature

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 09-0089 in the name of Immunex Corporation.

Respectfully submitted,



Paul B. Tran, Ph.D.  
Attorney/Agent for Applicants  
Registration No.: 41,565  
Phone: (805) 447-9768  
Date: January 15, 2004

Please send all future correspondence to:

US Patent Operations/PBT  
Dept. 4300, M/S 27-4-A  
AMGEN, INC.  
One Amgen Center Drive  
Thousand Oaks, CA 91320-1799

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO.

2009-US

SERIAL NO.

09/884,001

APPLICANT

Timothy A. Bird, et al.

FILING DATE

June 18, 2001

GROUP

1642

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
B1	WO 97/47750	12/18/97	PCT			
B2	WO 98/37094	8/27/98	PCT			
B3	WO 00/36097	6/22/00	PCT			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C1	Bains M., et al., "A Human Homologue (BICD1) Of The <i>Drosophila Bicaudal-D</i> Gene," <i>Genomics</i> 45(3):601-606, November 1, 1997.
C2	Ishikawa K., et al., "Prediction Of The Coding Sequence Of Unidentified Human Genes. X. The Complete Sequences Of 100 New cDNA Clones From Brain Which Can Code For Large Proteins <i>In Vitro</i> ," <i>DNA Research</i> 5(5):169-176, June 30 1998.
C3	Ohara O., et al., GenBank Accession No. AB014599, "Homo sapiens mRNA for KIAA0699 protein, partial cds," July 15, 1998.
C4	Sato N., et al., "Actions of TNF and IFN- $\gamma$ on Angiogenesis <i>In Vitro</i> ," <i>J. Investigative Dermatology</i> 95:85S-89S, December 1, 1990.

EXAMINER

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.